Latest treatment guidelines from the American College of Cardiology, for people at very high risk.
They continue to recommend high-intensive statin treatment for anyone diagnosed with acute coronary syndrome (ACS), with the option of adding ezetimibe. This population is at very high risk.
Acute coronary syndrome (ACS) is a group of heart conditions that involve significant reduction in blood flow to the heart muscle. ACS is typically caused by the buildup of plaque in the coronary arteries, which supply blood to the heart.
In addition, they recommend adding an additional non-statin agent for anyone with ACS with LDL over 70 md/dL, who is already at max tolerated statin dose.
They also state that it is “reasonable” to intensify use of additional non-statin agents in this case, even if LDL is as low as 55mg/dL. So they are leaving it at the discretion of the physician whether or not to drive LDL below 55 mg/dL in this case.
Quoted:
“High-intensity statin therapy is recommended for all patients with ACS, and with the option to initiate concurrent ezetimibe. A nonstatin lipid-lowering agent (eg, ezetimibe, evolocumab, alirocumab, inclisiran, bempedoic acid) is recommended for patients already on maximally tolerated statin who have a low-density lipoprotein cholesterol level of ≥70 mg/dL (1.8 mmol/L). It is reasonable in this high-risk population to further intensify lipid-lowering therapy if the low-density lipoprotein cholesterol level is 55 to <70 mg/dL (1.4 to <1.8 mmol/L) and patient is already on a maximally tolerated statin.”




